 |
|
 
|
|
|
| Atherogenics |
$48,000,000 |
Initial Public Offering |
| AutoImmune |
$56,000,000 |
Follow-On |
| Axys |
$44,900,000 |
Follow-On |
| Axys |
$17,500,000 |
Initial Public Offering |
| Caliper Technologies |
$83,000,000 |
Initial Public Offering |
| Centocor |
$132,800,000 |
Follow-On |
| Centocor |
$64,700,000 |
Follow-On |
| Cephalon |
$89,700,000 |
Follow-On |
| CoCensys |
$15,800,000 |
Follow-On |
| Connetics |
$22,800,000 |
Follow-On |
| Discovery Partners |
$103,500,000 |
Initial Public Offering |
| Dura |
$160,300,000 |
Follow-On |
| Dura |
$158,700,000 |
Follow-On |
| Durect |
$96,600,000 |
Initial Public Offering |
| Endovascular Tech. |
$24,000,000 |
Initial Public Offering |
| Exelixis Pharmaceuticals |
$118,000,000 |
Initial Public Offering |
| Genencor International |
$145,000,000 |
Initial Public Offering |
| Gensia |
$68,000,000 |
Follow-On |
| Gensia/Aramed |
$50,000,000 |
Initial Public Offering |
| Gilead |
$82,000,000 |
Follow-On |
| IGEN |
$30,000,000 |
Initial Public Offering |
| ImmuLogic |
$25,800,000 |
Follow-On |
| Incyte |
$92,300,000 |
Follow-On |
| Incyte |
$34,900,000 |
Follow-On |
| Intermune |
$125,000,000 |
Initial Public Offering |
| Invitrogen |
$147,500,000 |
Follow-On |
| I-Stat |
$35,200,000 |
Follow-On |
| King |
$91,900,000 |
Initial Public Offering |
| Lexicon Genetics |
$220,000,000 |
Initial Public Offering |
| Ligand |
$38,000,000 |
Follow-On |
| Medicis |
$197,000,000 |
Follow-On |
| NeoPath |
$60,000,000 |
Follow-On |
| Novoste |
$55,200,000 |
Follow-On |
| OrthoLogic |
$78,400,000 |
Follow-On |
| Protein Design Labs, Inc. |
$362,000,000 |
Follow-On |
| SangStat |
$78,000,000 |
Follow-On |
| SangStat |
$42,000,000 |
Follow-On |
| Shire |
$100,000,000 |
Follow-On |
| Sonus |
$20,000,000 |
Initial Public Offering |
| SpectRx |
$15,400,000 |
Initial Public Offering |
| Sugen |
$24,800,000 |
Follow-On |
| Sulzer Medica |
$620,000,000 |
Initial Public Offering |
| Telik |
$35,000,000 |
Initial Public Offering |
| Uromed |
$40,000,000 |
Initial Public Offering |
| Variagenics |
$88,000,000 |
Initial Public Offering |
| Versicor |
$50,600,000 |
Initial Public Offering |
| |
|
|
| *Transactions completed by principals, including those completed at other firms. |
|
|
|
|
|
|
|
